Envudeucitinib vs zasocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Envudeucitinib
Developed by Alumis and partners
NCT06586112 · Phase 3 · completed
Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT05739435 (registry estimate)
Reported efficacy
To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)
Result source: NCT06586112
zasocitinib
Developed by Takeda Pharmaceutical Company
NCT06108544 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07752108 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)
Result source: NCT06973291
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Envudeucitinib | zasocitinib |
|---|---|---|
| PASI 75 | 56.4% vs 0%+56.4 vs placeboNCT056000364 other results
| 67.3% vs 5.8%+61.5 vs placeboNCT049998394 other results
|
| PASI 90 | —Not posted · NCT06588738 | 46.2% vs 0%+46.2 vs placeboNCT049998393 other results
|
| PASI 100 | —Not posted · NCT06588738 | 32.7% vs 0%+32.7 vs placeboNCT049998393 other results
|
| sPGA 0/1 | 53.8% vs 7.9%+45.9 vs placeboNCT056000364 other results
| 51.9% vs 3.8%+48.1 vs placeboNCT049998395 other results
|
| DLQI, change | —Not posted · NCT06588738 | -8.9 vs -4.9−4 vs placeboNCT049998393 other results
|
PASI 75
- Envudeucitinib
- 56.4% vs 0%+56.4 vs placeboNCT05600036
4 other results
- 64.1% vs 0% NCT05600036
- 33.3% vs 0% NCT05600036
- 56.4% vs 0% NCT05600036
- 19.4% vs 0% NCT05600036
- zasocitinib
- 67.3% vs 5.8%+61.5 vs placeboNCT04999839
4 other results
- 67.9% vs 5.8% NCT04999839
- 44.2% vs 5.8% NCT04999839
- 18% vs 5.8% NCT04999839
- 75.7% vs 12.1% NCT06088043
PASI 90
- Envudeucitinib
- —Not posted · NCT06588738
- zasocitinib
- 46.2% vs 0%+46.2 vs placeboNCT04999839
3 other results
- 45.3% vs 0% NCT04999839
- 21.2% vs 0% NCT04999839
- 8% vs 0% NCT04999839
PASI 100
- Envudeucitinib
- —Not posted · NCT06588738
- zasocitinib
- 32.7% vs 0%+32.7 vs placeboNCT04999839
3 other results
- 15.1% vs 0% NCT04999839
- 9.6% vs 0% NCT04999839
- 2% vs 0% NCT04999839
sPGA 0/1
- Envudeucitinib
- 53.8% vs 7.9%+45.9 vs placeboNCT05600036
4 other results
- 59% vs 7.9% NCT05600036
- 38.9% vs 7.9% NCT05600036
- 48.7% vs 7.9% NCT05600036
- 16.7% vs 7.9% NCT05600036
- zasocitinib
- 51.9% vs 3.8%+48.1 vs placeboNCT04999839
5 other results
- 49.1% vs 3.8% NCT04999839
- 26.9% vs 3.8% NCT04999839
- 10% vs 3.8% NCT04999839
- 69.2% vs 12.6% NCT06108544
- 71.4% vs 10.7% NCT06088043
DLQI, change
- Envudeucitinib
- —Not posted · NCT06588738
- zasocitinib
- -8.9 vs -4.9−4 vs placeboNCT04999839
3 other results
- -8.5 vs -4.9 NCT04999839
- -7.9 vs -4.9 NCT04999839
- -5.3 vs -4.9 NCT04999839
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Envudeucitinib: 4 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Envudeucitinib | zasocitinib |
|---|---|---|
| Dropout rate | 10.3%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results15.4%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.5%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 16.7%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence | 9.6%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results13.2%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 13.5%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 16%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 5.6%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 0%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence | 1.9%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 1.9%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 2%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%40mg BIDa NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results2.6%40mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 7.7%20mg BID NCT05600036 · Phase 2 · registry result, not featured evidence 0%20mg QD NCT05600036 · Phase 2 · registry result, not featured evidence 2.8%10mg QD NCT05600036 · Phase 2 · registry result, not featured evidence | 0%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40mg BIDa headache 7.7% (placebo 5.3%) nasopharyngitis 7.7% (placebo 7.9%) upper respiratory tract infection 7.7% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence show 4 more results40mg QD headache 10.3% (placebo 5.3%) acne 5.1% (placebo 0%) upper respiratory tract infection 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg BID headache 7.7% (placebo 5.3%) cough 5.1% (placebo 0%) diarrhea 5.1% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 20mg QD headache 5.6% (placebo 5.3%) upper respiratory tract infection 5.6% (placebo 0%) acne 0% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence 10mg QD diabetes mellitus 5.6% (placebo 0%) nasopharyngitis 5.6% (placebo 7.9%) upper respiratory tract infection 5.6% (placebo 0%) NCT05600036 · Phase 2 · registry result, not featured evidence | 30 mga covid-19 13.5% (placebo 1.9%) blood creatine phosphokinase increased 5.8% (placebo 3.8%) dermatitis acneiform 5.8% (placebo 0%) NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results15 mg covid-19 11.3% (placebo 1.9%) acne 5.7% (placebo 0%) blood creatine phosphokinase increased 5.7% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 5 mg covid-19 7.7% (placebo 1.9%) lymphocyte count decreased 5.8% (placebo 0%) blood creatine phosphokinase increased 3.8% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 2 mg covid-19 12% (placebo 1.9%) alanine aminotransferase increased 6% (placebo 0%) diarrhoea 6% (placebo 1.9%) NCT04999839 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
zasocitinib
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · zasocitinib's landscape